The company's Q3FY25 consolidated profit plunged 63.6 percent to Rs 3.68 crore versus Rs 10.1 crore, while revenue rose 12.5 ...

Piramal Pharma shares will be in focus after the US FDA's GMP inspection at its Turbhe facility from February 11-17, 2025, ...

Piramal Pharma slipped 1.14% to Rs 195.40 after the US FDA issued a Form-483 with 6 observations to the company's Turbhe facility post a GMP inspection.

The company stated that the observations primarily pertain to procedural improvements and are not related to data integrity.

Piramal Pharma's Turbhe facility in Navi Mumbai receives six observations from U.S. FDA inspection, company preparing detailed response.

Zydus Lifesciences Chairman Pankaj R Patel believes India can deliver 100 new drugs by 2047, emphasizing the need for ...

Piramal Pharma has awarded its integrated media mandate to OMD India, part of Omnicom Media Group. Following a multi-round ...

Pankaj R Patel, Chairman of Zydus Lifesciences, envisions India delivering 100 new drugs by 2047, highlighting the importance of research, innovation, and capable human resources. He addressed myths ...

Find Piramal Pharma Ltd. Technical Chart BSE Analysis on The Economic Times. Get Piramal Pharma Ltd. Technical Charts Real-time and intraday charts, Piramal Pharma Ltd. Stock Analysis, and more.

As part of the mandate, OMD will focus on improving Piramal Pharma’s market presence, brand awareness, consumer engagement, ...

The observations are mainly procedural and do not indicate any data integrity issues, Piramal Pharma added in a regulatory ...

Zydus Lifesciences Chairman Pankaj R Patel predicts that the Indian pharmaceutical industry can develop 100 new drugs by 2047 ...